Indivior Pharmaceuticals, Inc. (INDV)
Nasdaq: INDV · Pharmaceutical Preparations · North Chesterfield, VA · filing with the SEC since 2014
Who owns Indivior Pharmaceuticals, Inc.
As filed with the SECHolders of 5% or more
4
Blackrock, Inc. holds 14.3% of Common Stock, as its SCHEDULE 13G/A filed Jan 8, 2026 says.
Directors and officers
22
report now, of 22 people on the record since 2026. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
Blackrock, Inc.
SCHEDULE 13G/A · filed Jan 8, 2026 · Common Stock · 6.8% in Jul 17, 2025
Vanguard Portfolio Management
SCHEDULE 13G · filed Apr 28, 2026 · Common Stock
Millennium Management LLC
SCHEDULE 13G · filed Sep 30, 2026 · Common Stock, par value $0.001 per share · 3.8% in Mar 23, 2026
Vanguard Capital Management
SCHEDULE 13G · filed Apr 27, 2026 · Common Stock
Two Seas Capital LP
SCHEDULE 13D/A · filed Dec 23, 2025 · Ordinary Shares, $0.50 nominal value per share · reported falling below 5%, from 5.7% in Dec 10, 2025
Fuller & Thaler Asset Management, Inc.
SCHEDULE 13G/A · filed May 13, 2026 · Common Stock · reported falling below 5%, from 5.1% in Feb 17, 2026
Deerfield Mgmt, L.P.
SCHEDULE 13G/A · filed Nov 13, 2025 · Ordinary Shares, $0.50 nominal value per share · reported falling below 5%, from 8.47% in May 13, 2025
Morgan Stanley
SCHEDULE 13G/A · filed May 6, 2025 · Ordinary Shares · reported falling below 5%
Madison Avenue International LP
SCHEDULE 13G/A · filed May 15, 2026 · Common stock, $0.001 par value per share (the "Common Stock") · reported falling below 5%, from 5% in Feb 17, 2026
Goldman Sachs Group Inc.
SCHEDULE 13G/A · filed Feb 12, 2026 · Common Stock, par value $0.001 per share · reported falling below 5%, from 5.2% in Nov 12, 2025
Oaktree Capital Holdings, LLC
SCHEDULE 13D/A · filed Aug 13, 2026 · Common stock, $0.001 par value per share · reported falling below 5%, from 5.69% in Dec 30, 2025
What INDV reports owning in othersstakes of 5% or more, and other ties
31 subsidiaries in 14 countries, from the list filed with the 10-K filed Feb 26, 2026.
Insider tradesForm 4
3sales
10purchases
3sales on a scheduled plan
2people selling
$2.8Msold, in dollars
$300,000bought, in dollars
Open-market trades on Form 4 from Nov 4, 2025 to Nov 4, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 4, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window9 of 22 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Heidbreder Christian | Chief Scientific Officer | 2 | $1.5M | 2 | 0 | $0 |
| Preblick Ryan | Chief Financial Officer | 1 | $1.4M | 1 | 0 | $0 |
| Ryan Barbara | director | 0 | $0 | 0 | 3 | $0 |
| Anderson Woodrow D | Chief Accounting Officer | 0 | $0 | 0 | 2 | $100,000 |
| Humphreys Keith | director | 0 | $0 | 0 | 1 | $0 |
| Kingsley Stuart A | director | 0 | $0 | 0 | 1 | $0 |
| Ninivaggi Daniel A | director | 0 | $0 | 0 | 1 | $0 |
| Stejbach Mark | director | 0 | $0 | 0 | 1 | $0 |
| Wheadon David E. | director | 0 | $0 | 0 | 1 | $100,000 |